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Treatment of vascular calcification
W. Charles O’Neill1
A variety of potential therapies for vascular calcification, based either 
on the underlying biology or physical chemistry or solely on empiric 
observations in patients, may be effective but lack rigorous testing. 
Pasch et al. provide convincing evidence that sodium thiosulfate 
prevents medial vascular calcification in uremic rats. Although this 
provides some scientific basis for the clinical use of thiosulfate, 
uncertainty about mechanism of action and safety still remains.
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One manifestation of the accelerated 
vascular disease in chronic kidney dis-
ease (CKD) is calcification of the medial 
(muscular) layer of large and small arter-
ies. This should be distinguished from 
intimal calcification, which is associated 
with atherosclerosis and occurs in both 
the absence and the presence of CKD. 
Medial calcification occurs on elastic fib-
ers between the layers of smooth muscle 
and cannot be ascribed solely to hyper-
phosphatemia, since it occurs in the 
absence of hyperphosphatemia in aging 
and diabetes. The etiology is almost cer-
tainly multifactorial, involving changes in 
smooth muscle factors that both inhibit 
and promote calcification, as well as ambi-
ent calcium and phosphate levels.
The first consideration in treating 
medial calcification is whether it is harm-
ful. Humans lacking an enzyme that 
synthesizes extracellular pyrophosphate, 
a potent calcification inhibitor, develop 
severe medial calcification that causes 
death at a very young age unless treated.1 
Abundant data demonstrate that vascu-
lar calcification is associated with poorer 
outcomes in CKD and end-stage renal 
disease, and the reduction in vascular 
calcification with sevelamer compared 
with calcium-containing phosphate bind-
ers is associated with reduced mortality.2 
Unfortunately, the imaging techniques 
used cannot distinguish between intimal 
and medial calcification. Despite this 
limitation, these data strongly suggest that 
treatment or prevention of medial calci-
fication is beneficial, and it is difficult to 
imagine otherwise.
Treatment of medial calcification has 
generally been limited to optimizing the 
management of mineral metabolism and 
metabolic bone disease, to which it is 
inextricably linked. However, several fac-
tors probably limit the effectiveness of this 
approach. First, most phosphate binders 
provide a significant calcium load. Sec-
ond, calcitriol and calcitriol analogues 
may increase medial calcification, either 
through direct actions on vascular smooth 
muscle or by raising circulating calcium 
levels. Lastly, smooth muscle−specific fac-
tors that promote and inhibit calcification 
are not addressed by this strategy.
Another approach is to directly interfere 
with the calcification process (Figure 1). 
A seemingly safe way to do this would be 
to use calcification inhibitors normally 
present in vascular smooth muscle, of 
which pyrophosphate is the most feasi-
ble. Although pyrophosphate prevents 
medial calcification in vitamin D−toxic 
rats,3 very high doses are required 
because of rapid hydrolysis to ortho-
phosphate. To circumvent this problem, 
bisphosphonates were developed in the 
1960s as non-hydrolyzable analogues 
of pyrophosphate and have proven to 
be potent inhibitors of medial calcifi-
cation in uremic rats.4 An alternative 
approach to raising pyrophosphate levels 
is to inhibit tissue-nonspecific alkaline 
phosphatase (TNAP), an ectoenzyme 
that hydrolyzes pyrophosphate. This is 
particularly attractive because TNAP is 
upregulated in uremic arteries.5 Potent 
specific inhibitors of TNAP have recently 
been developed and inhibit smooth mus-
cle calcification in vitro.6 Magnesium 
also inhibits hydroxyapatite formation 
and could be an effective substitute for 
calcium in phosphate binders. Clinical 
efficacy has not been proven for any of 
these agents, and there are significant 
concerns about safety.
In 1985, Yatzidis first proposed the use 
of sodium thiosulfate to prevent kidney 
stones,7 and Yatzidis and Agroyannis sub-
sequently used it to treat tumoral calcifi-
cations in renal failure.8 The first reports 
of thiosulfate to treat calcific uremic arte-
riolopathy (CUA; formerly known as cal-
ciphylaxis) appeared four years ago, and 
it is now commonly used to treat CUA 
despite the lack of any clinical or basic 
studies demonstrating whether it works, 
how it works, and, most importantly, 
whether it is safe. This has been possible 
because sodium thiosulfate is already 
approved for clinical use in the treatment 
of cyanide toxicity.
It is this uncertainty that forms the 
backdrop for the important new contri-
bution of Pasch et al.9 (this issue). These 
authors used a model of renal failure based 
on addition of adenine to the diet, which 
produces severe interstitial nephritis and 
uremia, with medial vascular calcification 
developing within 4 weeks. Thiosulfate 
completely prevented calcification in this 
model at a dose and interval compara-
ble to those used in humans with CUA, 
thus providing a scientific basis for its 
clinical use. However, this is a model of 
large-artery calcification, not CUA, and 
the pathogenesis may not be the same. 
Also, this model of renal failure is associ-
ated with marked polyuria and salt wast-
ing rather than the oliguria and sodium 
retention in dialysis patients, which could 
differentially affect thiosulfate levels and 
calcium balance.
1Renal Division, Department of Medicine, Emory 
University School of Medicine, Atlanta, Georgia, 
USA
Correspondence: W. Charles O’Neill, Department 
of Medicine, Emory University School of Medicine, 
WMB 338, 1639 Pierce Drive, Atlanta, Georgia 
30322, USA. 
E-mail: woneill@emory.edu
Kidney International (2008) 74          1377
commentar y
Despite careful measurement of mul-
tiple biochemical parameters by the 
authors, the mechanism by which calci-
fication was prevented remains unclear. 
Notably, there were no significant changes 
in serum calcium, phosphate, or parathy-
roid hormone levels. However, the serum 
calcium level was adjusted for albumin 
concentration, and this adjustment could 
be altered by thiosulfate. Recognizing 
this, the authors performed short-term 
measurements of ionized calcium and 
parathyroid hormone immediately after 
administration of thiosulfate. There was 
a transient decrease in ionized calcium, 
which the authors suggest could represent 
an interaction between calcium ions and 
thiosulfate ions but could just as easily 
have been dilutional. There was a delayed 
increase in total serum calcium that was 
accompanied by an increase in ionized 
calcium. Although the former might have 
been proportionally greater than the lat-
ter, suggesting binding by thiosulfate, the 
effect is quite small and the delay is not 
consistent with a chemical interaction.
The most striking biochemical find-
ing was a marked increase in calcium 
excretion in the urine, which was also 
seen in non-uremic rats. Possible expla-
nations for this are the renal excretion of 
large amounts of the poorly reabsorbed 
thiosulfate anion and a large distal sodium 
delivery. However, calcium excretion does 
not increase in humans treated with thio-
sulfate,7 suggesting that the hypercalciuria 
is peculiar to this model. The hypercalciu-
ria could be preventing vascular calcifi-
cation through negative calcium balance, 
but this is unlikely without a long-term 
reduction in serum calcium or increase in 
parathyroid hormone.
Not surprisingly, the serum anion gap 
increased with a drop in bicarbonate con-
centration and pH. Since sodium thio-
sulfate is not an acid, the drop in serum 
bicarbonate is merely dilutional, leading 
to an expansion acidosis. This is consist-
ent with the fact that no decrease in pH 
was observed when sodium thiosulfate 
was added to blood in vitro. Neverthe-
less, hydroxyapatite formation and vas-
cular calcification are pH-dependent,10 
and metabolic acidosis can reduce aortic 
calcification in uremic rats.11 However, it 
is unlikely that the small changes in pH 
noted after thiosulfate administration can 
explain the complete prevention of aortic 
calcification. Because only one dose of 
thiosulfate was tested, it is not possible to 
correlate inhibition of vascular calcifica-
tion with the other effects of thiosulfate.
So, how is thiosulfate working? The 
answer probably lies in the ionic inter-
action between thiosulfate and calcium 
ions and the solubility of the undisso-
ciated Ca2+|S2O32– ion pair. Although 
some authors refer to this as chelation, 
that term is reserved for compounds 
that bind an ion at two or more sites, 
as if being gripped by a claw (the Greek 
word from which ‘chelate’ was derived). 
Ion pairing can be either tight or loose, 
depending on whether there are inter-
vening solvent molecules. Measure-
ments of CaS2O3 association constants 
have indicated that as much as 10% of 
the thiosulfate in biological fluids may 
be in the form of soluble Ca2+|S2O32– 
ion pairs.12 Thus, at the concentrations 
of thiosulfate achieved in plasma in this 
study and in humans (5 mM or more), 
there would be up to 0.5 mM of this ion 
pair. However, no such increase in total 
calcium was observed by Pasch et al.,9 
there were no signs of hypocalcemia, 
and the changes in ionized calcium lev-
els produced by thiosulfate in vitro were 
much less than predicted by this degree 
of ion pairing. This discrepancy between 
the extent of ion pairing and the mini-
mal effects on total and ionized calcium 
levels suggests that the Ca2+|S2O32– ion 
pairing is quite loose, which is consist-
ent with the greater attraction of calcium 
ions to water molecules than to thiosul-
fate ions. A decrease in ionized calcium 
was observed in the urine of humans 
treated with thiosulfate,7 but this may be 
explained by the lower pH affecting the 
hydration of calcium ions.
It is important to note that Pasch et 
al.9 demonstrate prevention of medial 
calcification rather than reversal. The 
loose ion pairing of calcium and thio-
sulfate ions is probably sufficient to 
interfere with CaHPO4 formation but 
not strong enough to mobilize calcium 
from calcifications (W.C.O., unpublished 
data). The decrease in calcium deposits 
noted in case reports could be due to 
the combination of inhibition of further 
Figure 1 | Potential therapies for medial vascular calcification. Medial calcification is an 
extracellular event initiated by deposition of hydroxyapatite on elastin fibers. (1) The first step 
in this process is the formation of CaHPO4, which can be reduced by lowering phosphate 
concentrations. (2) Thiosulfate may inhibit this reaction by forming ion pairs with calcium ions. 
(3) Hydroxyapatite formation is normally inhibited by pyrophosphate (PPi) that is produced by 
vascular smooth muscle cells from adenosine triphosphate (ATP). Large doses of PPi have been 
shown to inhibit vascular calcification in vitamin D-toxic rats. (4) PPi is hydrolyzed by tissue-
nonspecific alkaline phosphatase (TNAP) on the smooth muscle membrane, and this could 
be targeted by newly developed TNAP inhibitors. (5) Bisphosphonates are non-hydrolyzable 
analogues of PPi that also inhibit hydroxyapatite formation in vitro. Because of their stability, they 
inhibit vascular calcification in rats at far lower doses than PPi. (6) Magnesium ions also inhibit 
hydroxyapatite in vitro at clinically relevant concentrations.
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calcification and concurrent measures to 
reduce calcium load. Thiosulfate is also 
an antioxidant, and an effect related to 
this cannot be ruled out.
Before we jump in and treat vascular 
calcification with direct inhibitors, it 
is important to realize that they could 
also inhibit hydroxyapatite formation 
in bone. Doses of bisphosphonates 
that inhibit vascular calcification can 
also reduce bone mineralization (K. 
Lomashvili et al., unpublished data), and 
the finding of decreased bone strength 
by Pasch et al.9 raises the same con-
cern with thiosulfate. Although some 
humans have been treated with thiosul-
fate for several years,7 they did not have 
renal failure, and bone was not exam-
ined. Bisphosphonates are retained in 
renal failure and can be incorporated 
into bone, which might also occur with 
thiosulfate. The results of Pasch et al.9 
are an important step in establishing the 
clinical utility of thiosulfate in treating 
vascular calcification, but subsequent 
studies will need to address mechanisms 
of action and the therapeutic window.
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